Last reviewed · How we verify
IV azithromycin
IV azithromycin is a macrolide antibiotic that binds to bacterial ribosomal RNA and inhibits protein synthesis, killing susceptible bacteria.
IV azithromycin is a macrolide antibiotic that binds to bacterial ribosomal RNA and inhibits protein synthesis, killing susceptible bacteria. Used for Community-acquired pneumonia, Acute bacterial exacerbation of chronic bronchitis, Acute bacterial sinusitis.
At a glance
| Generic name | IV azithromycin |
|---|---|
| Also known as | Zithromax® |
| Sponsor | Pfizer |
| Drug class | Macrolide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Azithromycin binds to the bacterial 50S ribosomal subunit, blocking peptide translocation and preventing bacterial protein synthesis. This bactericidal/bacteriostatic action is effective against a broad spectrum of gram-positive and gram-negative bacteria, as well as atypical organisms. The intravenous formulation allows for rapid systemic delivery in hospitalized or severely ill patients.
Approved indications
- Community-acquired pneumonia
- Acute bacterial exacerbation of chronic bronchitis
- Acute bacterial sinusitis
- Pelvic inflammatory disease
- Sexually transmitted infections (Chlamydia trachomatis, Neisseria gonorrhoeae)
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Phlebitis at injection site
- QT prolongation
- Hepatotoxicity
- Allergic reactions
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (PHASE2)
- Gastric CLEANsing by Intravenous AZithromycin in Urgent Endoscopy (NA)
- Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever (PHASE4)
- Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes (PHASE3)
- Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes (NA)
- Tebipenem Trial in Children With Shigellosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV azithromycin CI brief — competitive landscape report
- IV azithromycin updates RSS · CI watch RSS
- Pfizer portfolio CI